{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T21:58:48Z","timestamp":1790546328080,"version":"4.1.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"17","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T00:00:00Z","timestamp":1725235200000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.heliyon.2024.e37359","type":"journal-article","created":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T20:58:46Z","timestamp":1725310726000},"page":"e37359","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Impact of dosing strategy on clinical outcomes of patients with lupus nephritis initially treated with lower-than-recommended-dose cyclophosphamide"],"prefix":"10.1016","volume":"10","author":[{"given":"Kittiphan","family":"Chienwichai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aniwat","family":"Choomnirat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sorawat","family":"Sangkaew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nutthapong","family":"Sunanthamethee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0158-2685","authenticated-orcid":false,"given":"Arunchai","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.heliyon.2024.e37359_bib1","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1191\/0961203302lu158oa","article-title":"Systemic lupus erythematosus in three ethnic groups. XII. Risk factors for lupus nephritis after diagnosis","volume":"11","author":"Bastian","year":"2002","journal-title":"Lupus"},{"key":"10.1016\/j.heliyon.2024.e37359_bib2","doi-asserted-by":"crossref","first-page":"825","DOI":"10.2215\/CJN.05780616","article-title":"Update on lupus nephritis","volume":"12","author":"Almaani","year":"2017","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.heliyon.2024.e37359_bib3","article-title":"Adverse event burden, resource use, and costs associated with immunosuppressant medications for the treatment of systemic lupus erythematosus: a systematic literature review","volume":"2013","author":"Oglesby","year":"2013","journal-title":"Internet J. Rheumatol."},{"key":"10.1016\/j.heliyon.2024.e37359_bib4","doi-asserted-by":"crossref","first-page":"248","DOI":"10.7326\/0003-4819-135-4-200108210-00009","article-title":"Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis","volume":"135","author":"Illei","year":"2001","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.heliyon.2024.e37359_bib5","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1046\/j.1523-1755.2002.00279.x","article-title":"Cyclophosphamide pharmacokinetics and dose requirements in patients with renal insufficiency","volume":"61","author":"Haubitz","year":"2002","journal-title":"Kidney Int."},{"key":"10.1016\/j.heliyon.2024.e37359_bib6","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/BF00548589","article-title":"Effect of renal insufficiency on the pharmacokinetics of cyclophosphamide and some of its metabolites","volume":"19","author":"Juma","year":"1981","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.heliyon.2024.e37359_bib7","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s00280-019-03775-9","article-title":"Cyclophosphamide dose adjustment based on body weight and albuminemia in elderly patients treated with R-mini-CHOP","volume":"83","author":"Baudry","year":"2019","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.heliyon.2024.e37359_bib8","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ejca.2015.12.007","article-title":"Cyclophosphamide pharmacokinetics and pharmacogenetics in children with B-cell non-Hodgkin's lymphoma","volume":"55","author":"Veal","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.heliyon.2024.e37359_bib9","doi-asserted-by":"crossref","first-page":"406","DOI":"10.3389\/fphar.2020.00406","article-title":"Population pharmacokinetic, pharmacogenetic, and pharmacodynamic analysis of cyclophosphamide in Ethiopian breast cancer patients","volume":"11","author":"Ahmed","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.heliyon.2024.e37359_bib10","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/j.1365-2125.2006.02690.x","article-title":"Relationship of glutathione S-transferase genotypes with side-effects of pulsed cyclophosphamide therapy in patients with systemic lupus erythematosus","volume":"62","author":"Zhong","year":"2006","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.heliyon.2024.e37359_bib11","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.fertnstert.2009.03.034","article-title":"Association of cyclophosphamide drug-metabolizing enzyme polymorphisms and chemotherapy-related ovarian failure in breast cancer survivors","volume":"94","author":"Su","year":"2010","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.heliyon.2024.e37359_bib12","first-page":"1009","article-title":"Relations between polymorphisms in drug-metabolising enzymes and toxicity of chemotherapy with cyclophosphamide, thiotepa and carboplatin, Pharmacogenet","volume":"18","author":"Ekhart","year":"2008","journal-title":"Genomics"},{"key":"10.1016\/j.heliyon.2024.e37359_bib13","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s12882-016-0361-0","article-title":"Outcome of low dose cyclophosphamide for induction phase treatment of lupus nephritis, a single center study","volume":"17","author":"Sigdel","year":"2016","journal-title":"BMC Nephrol."},{"key":"10.1016\/j.heliyon.2024.e37359_bib14","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2015-000123","article-title":"A proteinuria cut-off level of 0.7 g\/day after 12 months of treatment best predicts long-term renal outcome in lupus nephritis: data from the MAINTAIN Nephritis Trial","volume":"2","author":"Tamirou","year":"2015","journal-title":"Lupus Sci. Med."},{"key":"10.1016\/j.heliyon.2024.e37359_bib15","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2017-000213","article-title":"Early proteinuria response: a valid real-life situation predictor of long-term lupus renal outcome in an ethnically diverse group with severe biopsy-proven nephritis?","volume":"4","author":"Ugolini-Lopes","year":"2017","journal-title":"Lupus Sci. Med."},{"key":"10.1016\/j.heliyon.2024.e37359_bib16","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000009408","article-title":"Systematic evaluation of different doses of cyclophosphamide induction therapy for lupus nephritis","volume":"96","author":"Tian","year":"2017","journal-title":"Medicine"},{"key":"10.1016\/j.heliyon.2024.e37359_bib17","doi-asserted-by":"crossref","first-page":"3248","DOI":"10.1093\/ndt\/gfs073","article-title":"Survival analysis and causes of mortality in patients with lupus nephritis","volume":"27","author":"Yap","year":"2012","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.heliyon.2024.e37359_bib18","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJM198603063141004","article-title":"Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs","volume":"314","author":"Austin","year":"1986","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.heliyon.2024.e37359_bib19","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1002\/art.10461","article-title":"Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide","volume":"46","author":"Houssiau","year":"2002","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.heliyon.2024.e37359_bib20","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.2217\/pgs.09.134","article-title":"Drug focus: pharmacogenetic studies related to cyclophosphamide-based therapy","volume":"10","author":"Pinto","year":"2009","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.heliyon.2024.e37359_bib21","first-page":"187","article-title":"Gene signature-based prediction of tumor response to cyclophosphamide","volume":"4","author":"Korrat","year":"2007","journal-title":"Cancer Genomics Proteomics"},{"key":"10.1016\/j.heliyon.2024.e37359_bib22","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1002\/art.20338","article-title":"Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis","volume":"50","author":"Takada","year":"2004","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.heliyon.2024.e37359_bib23","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s00280-021-04389-w","article-title":"Effects of cyclophosphamide related genetic variants on clinical outcomes of adult hematopoietic cell transplant patients","volume":"89","author":"Takahashi","year":"2022","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.heliyon.2024.e37359_bib24","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1038\/leu.2008.398","article-title":"Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large B-cell lymphoma treated with R-CHOP21","volume":"23","author":"Rossi","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.heliyon.2024.e37359_bib25","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1007\/s00228-018-2505-6","article-title":"Association of CYP2C192 and ALDH1A11\/*2 variants with disease outcome in breast cancer patients: results of a global screening array","volume":"74","author":"Kalra","year":"2018","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.heliyon.2024.e37359_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtauto.2020.100078","article-title":"Bacterial infections in lupus: roles in promoting immune activation and in pathogenesis of the disease","volume":"4","author":"Battaglia","year":"2021","journal-title":"J. Transl. Autoimmun."},{"key":"10.1016\/j.heliyon.2024.e37359_bib27","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1177\/0961203319826690","article-title":"Factors predictive of long-term mortality in lupus nephritis: a multicenter retrospective study of a Japanese cohort","volume":"28","author":"Ichinose","year":"2019","journal-title":"Lupus"},{"key":"10.1016\/j.heliyon.2024.e37359_bib28","doi-asserted-by":"crossref","first-page":"46","DOI":"10.2215\/CJN.03280807","article-title":"Value of a complete or partial remission in severe lupus nephritis","volume":"3","author":"Chen","year":"2008","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.heliyon.2024.e37359_bib29","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa2001180","article-title":"Two-year, randomized, controlled trial of belimumab in lupus nephritis","volume":"383","author":"Furie","year":"2020","journal-title":"N. Engl. J. Med."}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024133907?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024133907?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T21:33:03Z","timestamp":1790544783000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844024133907"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":29,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S2405844024133907"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e37359","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of dosing strategy on clinical outcomes of patients with lupus nephritis initially treated with lower-than-recommended-dose cyclophosphamide","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e37359","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e37359"}}